Prevention of Breast Cancer (Part II): Risk Reduction Strategies

REFERENCES

• Parmigiani, G.; Berry, D.A.; Aguilar, O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet. 1998, 62, 145–158.
   PubMed Web of Science ®Google Scholar
• Antonio, A.C.; Cunningham, A.P.; Peto, J.; Evans, D.G.; Lalloo, F.; Narod, S.A.; Risch, H.A.; Eyfjord, J.E.; Hopper, J.L.; Southey, M.C.; Olsson, H.; Johannsson, O.; Borg, A.; Pasini, B.; Radice, P.; Manoukian, S.; Eccles, D.M.; Tang, N.; Olah, E.; Anton-Culver, H.; Warner, E.; Lubinski, J.; Gronwald, J.; Gorski, B.; Tryggvadottir, L.; Syrjakoski, K.; Kallioniemi, O.P.; Eerola, H.; Nevanlinna, H.; Pharoah, P.D.; Easton, D.F. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Brit J Cancer. 2008, 98, 1457– 1466.
   PubMed Web of Science ®Google Scholar
• Giuliano, A.E.; Boolbol, S.; Degnim, A.; Kuerer, H.; Leitch, A.M.; Morrow, M. Society of surgical oncology: position statement on prophylactic mastectomy. Approved by the society of surgical oncology executive council, March 2007. Ann Surg Oncol 2007, 14, 2425–2427.
   PubMed Web of Science ®Google Scholar
• Hartmann, L.C.; Schaid, D.J.; Woods, J.E.; Crotty, T.P.; Myers, J.L.; Arnold, P.G.; Petty, P.M.; Sellers, T.A.; Johnson, J.L.; McDonnell, S.K.; Frost, M.H.; Jenkins, R.B. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999, 340, 77–84.
   PubMed Web of Science ®Google Scholar
• Lostumbo, L.; Carbine, N.; Wallace, J.; Ezzo, J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev 2004 (4), CD002748,.
   PubMedGoogle Scholar
• Montgomery, L.L.; Tran, K.N.; Heelan, M.C.; Van Zee, K.J.; Massie, M.J.; Payne, D.K.; Borgen, P.I. Issues of regret in women with contralateral prophylactic mastectomies. Ann Surg Oncol 1999, 6(6), 546–552.
   PubMed Web of Science ®Google Scholar
• Parker, W.H.; Broder, M.S.; Chang E.; Feskanich, D.; Farquhar, C.; Liu, Z.; Shoupe, D.; Berek, J.S.; Hankinson, S.; Manson, J.E. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses’ health study. Obstetrics & Gynecology 2009, 113, 1027–1037.
   PubMed Web of Science ®Google Scholar
• Rebbeck, T.R.; Levin, A.M.; Eisen, A.; Snyder, C.; Watson, P.; Cannon-Albright, L.; Isaacs, C.; Olopade, O.; Garber, J.E.; Godwin, A.K.; Daly, M.B.; Narod, S.A.; Neuhausen, S.L.; Lynch, H.T.; Weber, B.L. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999, 91(17), 1475–1479.
   PubMed Web of Science ®Google Scholar
• Kauff, N.D.; Satagopan, J.M.; Robson, M.E.; Scheuer, L.; Hensley, M.; Hudis, C.A.; Ellis, N.A.; Boyd, J., Borgen, P.I.; Barakat, R.R.; Norton, L.; Castiel, M.; Nafa, K.; Offit, K. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2006, 346(21), 1609–1615.
   Google Scholar
• Rebbeck, T.R.; Lynch, H.T.; Neuhausen, S.L.; Narod, S.A.; Van't Veer, L.; Garber, J.E.; Evans, G.; Isaacs, C.; Daly, M.B.; Matloff, E.; Olopade, O.I.; Weber, B.L. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002, 346(21), 1616–1622.
   PubMed Web of Science ®Google Scholar
• Tamoxifen for early breast cancer: an overview of the randomized trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1998, 351, 1451–1467.
   PubMedGoogle Scholar
• Fisher, B.; Constantino, J.P.; Wickerman, D.L.; Redmond, C.K.; Kavanah, M.; Cronin, W.M.; Vogel, V.; Robidoux, A.; Dimitrov, N.; Atkins, J.; Daly, M.; Wieand, S.; Tan-Chiu, E.; Ford, L.; Wolmark, N. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 1998, 90, 1371–1388.
   PubMed Web of Science ®Google Scholar
• Fisher, B.; Constantino, J.P.; Wickerman, D.L.; Cecchini, R.S.; Cronin, W.M.; Robidoux, A.; Bevers, T.B.; Kavanah, M.T.; Atkins, J.N.; Margolese, R.G.; Runowicz, C.D.; James, J.M.; Ford, L.G.; Wolmark, N. Tamoxifen for prevention of breast cancer: current status of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 2005, 97, 1652–1662.
   PubMed Web of Science ®Google Scholar
• Cuzick, J.; Forbes, J.F.; Edwards, R.; Baum, M.; Cawthorn, S.; Coates, A.; Hamed, A.; Howell, A.; Powles, T. First results from the international breast cancer interventional study (IBIS-1): a randomized prevention trial. Lancet 2002, 360, 817–824.
   PubMed Web of Science ®Google Scholar
• Cuzick, J.; Forbes, J.F.; Sestak, I.; Cawthorn, S.; Hamed, H.; Holli, K.; Howell, A. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-1 trial. J Natl Cancer Inst 2007, 99, 272–282.
   PubMed Web of Science ®Google Scholar
• Powles, T.J.; Ashley, S.; Tidy, A.; Smith, I.E.; Dowsett, M. Twenty-year follow-up of the Royal Marsden randomized double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 2007, 99, 283–290.
   PubMed Web of Science ®Google Scholar
• Veronesi, U.; Maisonneuve, P.; Rotmensz, N.; Bonanni, B.; Boyle, P.; Viale, G.; Costa, A.; Sacchini, V.; Travaglini, R.; D’Aiuto, G.; Oliviero, P.; Lovison, F.; Gucciardo, G.; del Turco, M.R.; Muraca, M.G.; Pizzichetta, M.A.; Conforti, S.; Decensi, A. Tamoxifen for the prevention of breast cancer: late results of the Italian randomized tamoxifen prevention trial among women with hysterectomy. J Natl Cancer Inst 2007, 99, 727–737.
   PubMed Web of Science ®Google Scholar
• Cummings, S.R.; Eckert, S.; Krueger, K.A.; Grady, D.; Powles, T.J.; Cauley, J.A.; Norton, L.; Nickelsen, T.; Bjarnason, N.H.; Morrow, M.; Lippman, M.E.; Black, D.; Glusman, J.E.; Costa, A.; Jordan, V.C. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial- Multiple Outcomes of Raloxifene Evaluation. JAMA 1999, 281, 2189–2197.
   Web of Science ®Google Scholar
• Martino, S.; Cauley, J.A.; Barrett-Connor, E.; Powles, T.J.; Mershon, J.; Disch, D.; Secrest, R.J.; Cummings, S.R. Continuing outcome relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene, J Natl Cancer Inst. 2004, 96, 1751–1761.
   PubMed Web of Science ®Google Scholar
• Barrett-Connor, E.; Mosca, L.; Collins, P.; Geiger, M.J.; Grady, D.; Kornitzer, M.; McNabb, M.A.; Wenger, N.K. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006, 355, 125–137.
   PubMed Web of Science ®Google Scholar
• Vogel, V.G.; Constantine, J.P.; Wickerham, D.L.; Cronin, W.M.; Cecchini, R.S.; Atkins, J.N., Bevers, T.B.; Fehrenbacher, L.; Pajon, E.R. Jr.; Wade, J.L. 3rd, Robidoux, A.; Margolese, R.G.; James, J.; Lippman, S.M.; Runowicz, C.D.; Ganz, P.A.; Reis, S.E.; McCaskill-Stevens, W.; Ford, L.G.; Jordan, V.C.; Wolmark, N. Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006, 295, 2727– 2741.
   PubMed Web of Science ®Google Scholar
• Cuzick, J.; Powles, T.; Veronesi, U.; Forbes, J.; Edwards, R.; Ashley, S.; Boyle, P. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003, 361, 296–300.
   PubMed Web of Science ®Google Scholar
• Braithwaite, R.R.S.; Chlebowski, R.T.; Lau, J.; George, S.; Hess, R.; Col, N.F. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med, 2003, 18, 937–947.
   PubMed Web of Science ®Google Scholar
• Bushnell, C.D.; Goldstein, L.B. Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis. Neurology 2004, 63, 1230–1233.
   PubMed Web of Science ®Google Scholar
• Paganini-Hill, A.; Clark, L.J. Preliminary assessment cognitive function in breast cancer patients treated with Tamoxifen. Breast Cancer Res Treat 2000, 64, 165–176.
   PubMed Web of Science ®Google Scholar
• Jenkins, V.; Shilling, V.; Fallowfield, L.; Howell, A.; Hutton, S. Does hormone treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychoncology 2004, 13, 61–66.
   PubMed Web of Science ®Google Scholar
• Yaffe, K.; Krueger, K.; Sarker, S.; Grady, D.; Barrett-Connor, E.; Cox, D.A.; Nickelsen, T. Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med 2001, 1207–1213.
   PubMed Web of Science ®Google Scholar
• Yaffe, K.; Krueger, K.; Cummings, S.R.; Blackwell, T.; Henderson, V.W.; Sarkar, S.; Ensrud, K.; Grady, D. Effect of raloxifene on dementia and cognitive impairment in older women: the multiple outcomes of raloxifene evaluation (MORE) randomized trial. Am J Psychiatry 2005, 162, 683–690.
   PubMed Web of Science ®Google Scholar
• Buckwalter, J.G.; Geiger, A.M.; Parsons, T.D.; Handler, J.; Howes, J.; Lehmer, R.R. Cognitive effects of short-term use of raloxifene: a randomized clinical trial. Int J Neurosci 2007, 1579–1590.
   PubMed Web of Science ®Google Scholar
• Day, R.; Ganz, P.A.; Costantino, J.P.; Cronin, W.M.; Wickerham, D.L.; Fisher, B. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the national surgical adjuvant breast and bowel project P-1 study. J Clin Oncol 1999, 17, 2659–2669.
   PubMed Web of Science ®Google Scholar
• The ATAC Trialists’ Group. Arimidex, tamoxifen alone or in combination. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 2002, 359(9324), 2131–2139.
   PubMed Web of Science ®Google Scholar
• Goss, P.E.; Ingle, J.N.; Martino, S.; Robert, N.J.; Muss, H.B.; Piccart, M.J.; Castiglione, M.; Tu, D.; Shepherd, L.E.; Pritchard, K.I.; Livingston, R.B.; Davidson, N.E.; Norton, L.; Perez, E.A.; Abrams, J.S.; Therasse, P.; Palmer, M.J.; Pater, J.L. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003, 349(19), 1793–802.
   PubMed Web of Science ®Google Scholar
• Coombes, R.C.; Hall, E.; Gibson, L.J.; Paridaens, R.; Jassem, J.; Delozier, T.; Jones, S.E.; Alvarez, I.; Bertelli, G.; Ortmann, O.; Coates, A.S.; Bajetta, E.; Dodwell, D.; Coleman, R.E.; Fallowfield, L.J.; Mickiewicz, E.; Andersen, J.; Lønning, P.E.; Cocconi, G.; Stewart, A.; Stuart, N.; Snowdon, C.F.; Carpentieri, M.; Massimini, G.; Bliss, J.M.; van de Velde, C. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004, 350(11), 1081–1092.
   PubMed Web of Science ®Google Scholar
• Dunn, B.K.; Ryan, A. Steroid enzymes and cancer: phase 3 trials of aromatase inhibitors for breast cancer prevention. Ann N Y. Acad Sci 2009, 1155, 141–161.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology, breast cancer risk reduction, V. 2.2009. Available at http://www.nccn.org . Accessed February 7, 2010.
   Google Scholar
• Visvanathan, K.; Chlebowski, R.T.; Hurley, P.; Col, N.F.; Ropka, M.; Collyar, D.; Morrow, M.; Runowicz, C.; Pritchard, K.I.; Hagerty, K.; Arun, B.; Garber, J.; Vogel, V.G.; Wade, J.L.; Brown, P.; Cuzick, J.; Kramer, B.S.; Lippman, S.M. American society of oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 2009, 27, 3235–3258.
   PubMed Web of Science ®Google Scholar
• Freedman, A.N.; Graubard, B.I.; Rao, S.R.; MMcCaskill-Stevens, W.; Ballard-Barbash, R.; Gail, M.H. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst. 2003, 95, 526–532.
   PubMed Web of Science ®Google Scholar